Targeted therapy for ovarian clear cell carcinoma, focusing on MET amplifcation and oxidative stress.

2016 Fiscal Year Final Research Report

• Project/Area Number: 26460423
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Human pathology
• Research Institution: Nagoya City University
• Principal Investigator: YAMASHITA Yoriko 名古屋市立大学, 大学院医学研究科, 准教授 (90303643)
• Co-Investigator(Renkei-kenkyūsha): TOYOKUNI Shinya 名古屋大学, 大学院医学系研究科, 教授 (90252460)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: Met遺伝子 / 卵巣明細胞癌 / 子宮体癌 / 乳癌

Outline of Final Research Achievements

At this moment, we do not have definite data about positive effects of Met inhibitors against transplanted ovarian clear cell carcinoma model. There are multiple reasons, but an important factor is that cell lines of ovarian clear cell carcinoma are slow-growing and difficult to obtain stable grafts in nude mice. We have analyzed tumors other than ovarian clear cell carcinomas, and Met amplification was confirmed in a subpopulation of endometrial cancers. On the other hand, breast cancers mostly had no amplification of the Met gene.

Free Research Field

人体病理学